Caricamento...
Low risk of hepatitis B reactivation in patients with severe COVID‐19 who receive immunosuppressive therapy
A significant proportion of patients infected with SARS‐CoV‐2 develop severe respiratory symptoms due to an excessive immune response. Treatment of this condition may include immunosuppressive therapies, such as IL‐6 receptor antagonists and corticosteroids, which pose a risk for patients with activ...
Salvato in:
| Pubblicato in: | J Viral Hepat |
|---|---|
| Autori principali: | , , , , , , , , |
| Natura: | Artigo |
| Lingua: | Inglês |
| Pubblicazione: |
John Wiley and Sons Inc.
2020
|
| Soggetti: | |
| Accesso online: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7537127/ https://ncbi.nlm.nih.gov/pubmed/32969557 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/jvh.13410 |
| Tags: |
Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !
|